Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial

with No hi ha comentaris
  • Corominas, J., Garriga, C., Prenafeta, A., Moros, A., Canete, M., Barreiro, A., . . . Ferrer, L. (2023). Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial. Lancet Regional Health-Europe, 28, Article 100613. https://doi.org/10.1016/j.lanepe.2023.100613

Deixa un comentari

L'adreça electrònica no es publicarà. Els camps necessaris estan marcats amb *